KMLE
»çÀÌÆ® ¼Ò°³
°Ë»ö
°Ë»ö¾î Áö¿ì±â
´Ý±â
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
°í±Þ °Ë»ö ¼³Á¤
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú :
14
ÆäÀÌÁö:
7
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
Æ®¸®»ìĸ½¶
Triflusal 300 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
357¿ø/1 °³
Æä´ÏµåÁ¤10mg
Methylphenidate HCl 10 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
188¿ø/1 °³
Æä´ÏµåÁ¤5mg
Methylphenidate HCl 5 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
136¿ø/1 °³
À¯¶õŹÁ¤150mg
Ranitidine HCl 168 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
382¿ø/1 °³
¶óÇÇ´ýÅ©¸²
Terbinafine HCl 10 mg
ȯÀÎÁ¦¾à
ÀϹÝ|»èÁ¦
0¿ø/1 °³
À¯¹Ù½Ç¸°ÁÖ1.5g
Ampicillin Sodium 1000 mg, Sulbactam Sodium 500 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
3713¿ø/1 °³
ÀڷϼҸ°Á¤10mg
Metolazone 10 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
345¿ø/1 °³
ÀڷϼҸ°Á¤5mg
Metolazone 5 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
219¿ø/1 °³
Å©·»Å¹ÁÖ2ml
Diclofenac Beta-Dimethyl Aminoethanol 90
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/2 °³
Å©·Î¹Ù°ÕÅ©¸²
Gentamicin Sulfate 1 mg/g, Betamethasone Dipropionate 640 ¥ìg/g
ȯÀÎÁ¦¾à
ÀϹÝ|»èÁ¦
0¿ø/1 °³
Æ®·¹Å½ÁÖ1g
Aztreonam 1 g
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
Æ®·¹Å½ÁÖ500mg
Aztreonam 500 mg
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
ȯÀγª·Ï¼ÕÁÖ5mg
Naloxone HCl 5
ȯÀÎÁ¦¾à
Àü¹®|»èÁ¦
0¿ø/1 °³
¶óÇÇ´ýÁ¤
Terbinafine HCl 142.62 mg
ȯÀÎÁ¦¾à
Àü¹®|±Þ¿©
668¿ø/1 °³
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
conversion rate
ÀüȯÀ²
conversion reaction
Àüȯ¹ÝÀÀ
convertase
Àüȯȿ¼Ò
converter
Àüȯ±â
converting enzyme inhibitor
Àüȯȿ¼Ò¾ïÁ¦Á¦
coronary circulation
°ü»óµ¿¸Æ¼øÈ¯, ½ÉÀ嵿¸Æ¼øÈ¯
coronary steal
°ü»óµ¿¸Æ½ºÆ¿, ½ÉÀåÇ÷·ùÀüȯ
cardiac
1. ½ÉÀå- 2. µé¹®-, ºÐ¹®- 3. ½ÉÀ庴ȯÀÚ
countercurrent exchange
¿ª·ù±³È¯
cremaster muscle
°íȯ¿Ã¸²±Ù, °íȯ°Å±Ù
cremasteric artery
°íȯ¿Ã¸²±Ùµ¿¸Æ, °íȯ°Å±Ùµ¿¸Æ
cremasteric fascia
°íȯ¿Ã¸²±Ù¸·, °íȯ°Å±Ù¸·
cremasteric reflex
°íȯ¿Ã¸²±Ù¹Ý»ç, °íȯ°Å±Ù¹Ý»ç
cretin
Å©·¹Æ¾º´È¯ÀÚ
critical care medicine
ÁßȯÀÚÄ¡·áÀÇÇÐ
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
transducer
º¯È¯±â, ŽÃËÀÚ
transsexualism
¼ºÀüȯÁõ
testis
°íȯ
testicular
°íȯ-
turnover
ȸÀü, ¹ÝÀü, Àüȯ
tunica vaginalis
°íȯÁý¸·
ectopic testis
µý°÷°íȯ(Áõ)
exchange transfusion
±³È¯¼öÇ÷
malignant transformation
¾Ç¼º¼¼Æ÷Àüȯ
metabolic turnover
´ë»çÀüȯ
substitution transfusion
(¢¡exchange transfusion) ±³È¯¼öÇ÷
testicular torsion
°íȯ²¿ÀÓ
torsion testis
(¢¡testicular torsion) °íȯ²¿ÀÓ
undescended testis
¾È³»·Á°£°íȯ, ¹ÌÇϰ°íȯ, ¹è¾È°íȯ
venting
¹è±â, ȯ±â
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
case finding program
ȯÀڹ߰߰èȹ, ȯÀڹ߰߻ç¾÷
spot map
ȯÀڹ߻ýÁöµµ
spot mapping
ȯÀڹ߻ýÁöµµÀÛ¼º
air ambulance
ȯÀÚ¼ö¼ÛºñÇà±â
sickrole behavior
ȯÀÚ¿ªÇÒÇàÅÂ
stretcher
ȯÀÚ¿î¹ÝÂ÷, µé°Í, ½ÅÀå±â
patient positioning
ȯÀÚÀ§Ä¡°áÁ¤
patient triggered respirator
ȯÀÚÀ¯¹ß½ÄÀΰøÈ£Èí±â
patient triggered ventilator
ȯÀÚÀ¯¹ßÈ£Èí±â
patient identification
ȯÀÚÈ®ÀÎ
phantom limb sensation
ȯÁö°¨, ȯ»óÆÈ´Ù¸®°¨°¢
phantom limb pain
ȯÁöÅë, ȯ»óÆÈ´Ù¸®ÅëÁõ
auditory hallucination
ȯû, µè±âȯ°¢
auditory hallucinosis
ȯûÁõ, ¼Ò¸®È¯°¢Áõ
tactile hallucination
ȯÃË, Ã˰¢È¯°¢
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
circular insanity
¼øÈ¯Á¤½ÅÀÌ»ó
circular reaction
¼øÈ¯¹ÝÀÀ
circulating blood volume
¼øÈ¯Ç÷¾×·®
circulatory collapse
¼øÈ¯ÇãÅ»
circulatory congestion
¼øÈ¯¿ïÇ÷
circulatory diffusion
¼øÈ¯È®»ê
circulatory failure
¼øÈ¯±â´É»ó½Ç, ¼øÈ¯ºÎÀü
circulatory shock
¼øÈ¯¼îÅ©
circulatory system
¼øÈ¯°èÅë
class switch
Ŭ·¡½ºÀüȯ
collar crown
´ëȯÀÇÄ¡°ü, Ä®¶ó°ü
collateral circulation
°ç¼øÈ¯
command hallucination
¸í·Éȯ°¢
commitment index
³»¿øÈ¯ÀÚÁö¿ªº°±¸¼ºµµ
community setting
Áö¿ª»çȸȯ°æ
ÀÌÀü
´ÙÀ½
Sponsored Links
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
alveolar gas exchange
ÆóÆ÷±âü±³È¯(¡Îß üµ)
alveolar gas exchange
ÆóÆ÷°¡½º±³È¯(¡Îß üµ).
alveolar hypoventilation
ÆóÆ÷Àúȯ±â(¡î¸üµÑ¨).
alveolar hypoventilation syndrome
ÆóÆ÷Àúȯ±âÁõÈıº.
alveolar ventilation
ÆóÆ÷ȯ±â(·®)
alveolar ventilation rate
ÆóÆ÷ȯ±âºñ(¡üµÑ¨Ýï)
alveolar ventilation volume
ÆóÆ÷ȯ±â¿ëÀû
analog to digital converter
¾Æ³ª·Î±× µðÁöÅ» º¯È¯±â
anchor band
À¯Áö´ëȯ(ë«ò¥Óáü»).
anchor clamp band
À¯Áö´ëȯ.
andersen disease
¾Ø´õ½¼º´<--Áúȯ>
anemia,myelophthisic
°ñ¼öġȯ¼º(ÍéâÐöÇüµàõ) (ºóÇ÷)(Þ¸úì)
angiocardiology
1. ½ÉÇ÷°üº´ÇÐ(ãýúìηܻ ùÊ). 2. ¼øÈ¯±âÇÐ(âàü»ÐïùÊ).
angiosis
Ç÷°üÁúȯ(úìηòðü´).
angiospasmodic disease
Ç÷°ü¿¬Ã༺ Áúȯ.
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ventilatory
ȯ±âÀÇ.
control of ventilation
ȯ±âÁ¶Àý(Ì·Ë»Ì¡Ëø).
control of ventilation
ȯ±âÁ¶Àý(üµÑ¨ðàï½).
ventilation index =VI
ȯ±âÁö¼ö(Ì·Ë» ̤Ëà).
ventilatory support
ȯ±âÁö¿ø(¡ò¨êµ).
reducibility
ȯ³³¼º(ü½Ò¡àõ), ȯ¿ø¼º (ü½êªàõ).
lantern test
ȯµî½ÃÇè(ÊÙËàÌ´).
rheotrope
ȯ·Î±â(üµÖØÐï).
reflux condenser
ȯ·ù³Ã°¢±â(¡ÕÒÊ¿Ðï).
gustatory hallucination
ȯ¹Ì
gustatory hallucination See hallucination
ȯ¹Ì(ü³Ú«).
hallucination, gustatory
ȯ¹Ì(ü³Ú«).
reduced heat
ȯ»ê¿·®(üµß©æðåÖ).
reduced mass
ȯ»êÁú·®(üµß©òõåÖ).
calibration scale
ȯ»êÇ¥(üµß©øú)
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
anomalies of systemic venous return
´ëÁ¤¸ÆÈ¯·ù(ÓÞð¡Øæü½êü)ÀÌ»ó.
anomalies of systemic venous return
´ëÁ¤¸ÆÈ¯·ù(ËÀ?ËÎÌ·Ëô)ÀÌ»ó.
anomalous pulmonary venous drainage
ÆóÁ¤¸ÆÈ¯·ù(øËð¡Øæü½êü)ÀÌ»ó.
anomalous pulmonary venous drainage
ÆóÁ¤¸ÆÈ¯·ù(̰?ËÎÌ·Ëô)ÀÌ»ó.
anomalous pulmonary venous return
ÆóÁ¤¸ÆÈ¯·ùÀÌ»ó.
anorchi(di)sm
¹«°íȯÁõ(ÙíÍÂü¯ñø).
anorchia
¹«°íȯ
anorchia congenital
¼±Ãµ¼º ¹«°íȯÁõ.
anorchism
°íȯ°á¿©Áõ
anterior atlanto-occipital membrane
¾ÕȯÃßÈĵθ·, ÀüȯÃßÈĵθ·(îñü» õÐýÔ騝
anterior embryotoxon
¾ÕÅ»ýȯ
antigenic diversion
Ç׿øÀüȯ(ù÷ê«ï®üµ).
antigenic transformation
Ç׿øº¯È¯(ù÷ê«Ü¨üµ).
antihallucinogen
Ç×ȯ°¢Á¦(ù÷ü³ÊÆð¥).
aortic configuration = sabot heart
´ëµ¿¸Æ(ÆÇ¸·Áúȯ) Çü»ó
ÀÌÀü
´ÙÀ½
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÇÑÀÚ
morbidity r.
ÀÌȯÀ²
ìºü´ëÒ
conversion r.
Àüȯ¹ÝÀÀ
ï®üµÚãëë
reduction
µÇ¸ÂÃã, ±³Á¤, ȯ¿ø, Ãà¼Ò
Îìïá, ü½êª, õêá³
cremasteric r.
°íȯ¿Ã¸²±Ù¹Ý»ç, °Å°í±Ù¹Ý»ç
ËáÍÂÐÉÚãÞÒ
replacement
±³È¯, ´ëÄ¡, ġȯ
Îßüµ, ÓÛöÇ, öÇüµ
reversion
µÇ¤±â, Àüȯ
ï®üµ
rotation
ȸÀü, µ¹¸², ¼øÈ¯
üÞï®, âàü»
circulatory s.
¼øÈ¯°è
âàü»Í§÷Ö
transforming growth factor
Àüȯ¼ºÀåÀÎÀÚ
ï®üµà÷íþì×í
transitional
Àüȯ¼º
ï®üµàõ
assist control v.
º¸Á¶Á¶Àýȯ±â
ÜÍð¾ðàï½üµÑ¨
control mode v.
Á¶Àý¸ðµåȯ±â
ðàクðµåüµÑ¨
intermittent mandatory v., IMV
°£Çæ°Á¦È¯±â
ÊàúÎîÜËð¤üµÑ¨
intermittent positive-pressure v.
°£Çæ¾ç¾Ðȯ±â
ÊàúÎåÕäâüµÑ¨
mechanical v.
±â°èȯ±â
ѦÌþîÜüµÑ¨
ÀÌÀü
´ÙÀ½
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
lysogenic conversion
¿ë¿øº¯È¯(éÁê«Ü¨üµ)
lysosomal disease
¶óÀ̼ÒÁ»Áúȯ(òðü´)
lysosomal storage disease
¶óÀ̼ÒÁ»³»(Ò®) ÀúÀåÁúȯ(îÍíúòðü´)
maple syrup urine disease
´Üdz½Ã·´´¢Áúȯ(Òãòðü´)
metabolic disease
´ë»çÁúȯ(ÓÛÞóòðü´)
metathesis
»óÈ£±³È¯(ßÓû»Îßüµ)
microenvironment
¹Ì¼¼È¯°æ(Ú°á¬ü»ÌÑ)
milieu interieur
³»ºÎȯ°æ(Үݻü»ÌÑ)
mucopolysaccharide storage disease
¹ÂÄÚ´Ù´çÁú(ÒýÓØòõ)ÀúÀåÁúȯ(îÍíúòðü´)
Niemann-Pick disease
´Ï¸¸-ÇÈ Áúȯ(òðü´)
nitrate reduction
Áú»êȯ¿ø(òòß«ü½êª)
nonpermissible substitution
ºñÇã¿ë ġȯ(ÞªúÉé»öÇüµ)
nonreducing sugar
ºñȯ¿ø´ç(Þªü½êªÓ×)
nucleophilic substitution
±¸ÇÙġȯ(Ï´ú·öÇüµ)
nucleotide exchange reaction
´©Å¬¸®¿ÀŸÀÌµå ±³È¯¹ÝÀÀ(ÎßüµÚãëë)
ÀÌÀü
´ÙÀ½
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
neuromuscular disease
½Å°æ±ÙÀ° Áúȯ
obstructive pulmonary disease
Æó¼â¼ºÆóÁúȯ
orchiditis
°íȯ¿°
orchiectomy
°íȯÀýÁ¦¼ú, Á¦°í¼ú
orchitis
°íȯ¿°
pelvic inflammatory disease
°ñ¹Ý¿°Áúȯ
peripheral vascular disease
¸»ÃÊÇ÷°üÁúȯ
phase frequency swap
À§»óÁ֯ļö±³È¯
photosensitizer
±¤°ú¹ÎȯÀÚ
polycystic disease
´Ù³¶¼ºÁúȯ
portal circulation
¹®¸Æ¼øÈ¯
prevalence
À¯Çà, ¿ì¼¼, À¯º´·ü, ÀÌȯÀ²
projector
ÇÁ·ÎÁ§ÅÍ, ¿µ»ç±â, ȯµî±â
PSTN [=public switched telephone network]
°øÁßÀüȸÁ, °øÁßÀüȱ³È¯¸Á
pulmonary circulation
Æó¼øÈ¯
ÀÌÀü
´ÙÀ½
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
7
ÄÚµå
¿µ¹®
ÇѱÛ
B94.8
Sequelae of other specified infectious and parasitic
±âŸ ¸í½ÃµÈ °¨¿°¼º ¹× ±â»ýÃæ¼º ÁúȯÀÇ ÈÄÀ¯Áõ
B94.9
Sequelae of unspecified infectious or parasitic disease
»ó¼¼ºÒ¸íÀÇ °¨¿°¼º ¶Ç´Â ±â»ýÃæ¼º ÁúȯÀÇ ÈÄÀ¯Áõ
B95
Streptococcus and staphylococcus as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ »ç½½¾Ë±Õ ¹× Æ÷µµ¾Ë±Õ
B95.0
Streptococcus, group A, as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ »ç½½¾Ë±Õ AÇ÷û±º
B95.1
Streptococcus, group B, as the cause of diseases classified to other chapters
´Ù¸¥ Àå¿¡¼ ºÐ·ùµÈ ÁúȯÀÇ ¿øÀÎÀ¸·Î¼ÀÇ »ç½½¾Ë±Õ BÇ÷û±º
ÀÌÀü
´ÙÀ½
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
¼³¸í
conversion disorder
Àüȯ Àå¾Ö
1. ±âÁúÀû ÁúȯÀÌ ¾øÀÌ ¹«ÀǽÄÀûÀÎ ¿ä±¸³ª °¥µîÀ¸·Î ÀÎÇÑ °¨°¢À̳ª ¿îµ¿ ±â´ÉÀÇ Àå¾Ö°¡ Ư¡ÀÎ Á¤½Å Áúȯ. 2. ½Å°æÇÐÀû ¶Ç´Â ³»°úÀû ÁúȯÀÌ ¾øÀÌ ¸¶ºñ, ½Ã·Â »ó½Ç, ÇÔ±¸Áõ
conversion factor
º¯È¯ °è¼ö
conversion rate
ÀüȯÀ²
convertase
Àüȯ È¿¼Ò
converting enzyme
Àüȯ È¿¼Ò
coronary risk factor
°ü»ó µ¿¸Æ Áúȯ À§Çè ¿äÀÎ
corpus epididymidis
ºÎ°íȯ ¸öÅë, ºÎ°íȯü
counter-poise
ġȯÀÇ
cremasteric artery
°íȯ ¿Ã¸²±Ù µ¿¸Æ
cricothyroid muscle
À±»ó °©»ó±Ù, ȯ»ó °©»ó±Ù
ȯ»ó ¿¬°ñ Àü¸é¿¡¼ ½ÃÀÛÇÏ¿© °©»ó ¿¬°ñ ÇÏ¿¬¿¡ ºÎÂøÇϸç, ÀÌ ±ÙÀ°ÀÌ ¼öÃàÇÏ¸é °©»ó ¿¬°ñÀ» ÀüÇϹæÀ¸·Î ȸÀü½ÃÄÑ ¼º´ëÀÇ ±äÀåµµ¸¦ Áõ°¡½ÃŲ´Ù.
Crohn's disease
Crohn Áúȯ, Å©·Ð¾¾ º´, Å©·Ð º´
Å©·ÐÀÌ 1932³â óÀ½À¸·Î ȸÀå ¸»´ÜÀÇ Àå¿°À» ±¹ÇÑÀû ȸÀå¿°À¸·Î ±âÀçÇÑ °Í. ȸÀå ¸»´Ü¿°. ¼ÒÀå, ´ëÀå¿¡¼µµ º¼ ¼ö ÀÖÀ¸¸ç ȸÀå ¸»´ÜºÎÀÇ °ÅÀÇ 30cm¿¡ ÀÚÁÖ ¹ß»ýÇϰí Á¡¸·¿¡¼ Á¡¸· ÇÏÃþ¿¡ ¹ÌÄ¡´Â ¿°Áõ¼º º¯È·Î À°¾Æ °Å´ë¼¼Æ÷¸¦ º¼ ¼ö ÀÖ´Ù. ¿øÀÎÀº Àå³» ¼¼±Õ, ¾Ë·¯Áö µîÀÇ ¿¬°üµÈ °ÍÀ¸·Î º¸ÀδÙ.
cryptorchidectomy
Àẹ °íȯ ÀýÁ¦
Á¤·ù °íȯÀ» ÀûÃâ Á¦°ÅÇÏ´Â °Í.
cyclarthrosis
Â÷Ãà °üÀý, Â÷Ãà ȯ»ó °üÀý
ȸÀüÇÒ ¼ö ÀÖ´Â °üÀý.
cycle
ÁÖ±â, ¼øÈ¯, Á֯ļö, »çÀÌŬ, Ç츣Âê, ¼øÈ¯ °úÁ¤, ȸ·Î
»ç°ÇÀ̳ª Áõ»óÀÇ ¿¬¼Ó. °üÃøµÇ´Â Çö»óÀÇ Àϼø, ¶Ç´Â ¿¬¼Ó. º¸ÅëÀº ±ÔÄ¢ÀûÀÎ °£°Ý°ú µ¿ÀÏÇÑ ¼ø¼·Î ¹Ýº¹µÈ´Ù.
cyclic
Áֱ⼺, ÁÖ±âÀÇ, Áֱ⼺ÀÇ, ¼øÈ¯ÀÇ, °í¸®ÀÇ
Áֱ⼺ÀÇ, ¼øÈ¯ÀÇ, ȯ»óÀÇ. ÀÌ ¿ë¾î´Â ¿øÀÚÀÇ °í¸®¸¦ ÇÔÀ¯ÇÑ ÈÇÕ¹°¿¡ ´ëÇÏ¿© »ç¿ëµÈ´Ù.
ÀÌÀü
´ÙÀ½
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú:
10
ÆäÀÌÁö:
7
ȯÀÎź»ê¸®Æ¬Á¤
A09701651
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Lithium carbonate
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
·Î¶ó¹ÝÁ¤1mg
G01000241
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Lorazepam
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
·Î¶ó¹ÝÁ¤0.5mg
G01000261
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Lorazepam
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
´º¸¶±×Á¤
A09750211
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Magnesium Lactate, Pyridoxine HCl
±¸ºÐ/º¸Çè±Þ¿©: ÀϹÝÀǾàǰ | ±Þ¿©
¾Æ´Ï½ºÆ¾Á¤
A09702431
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Mequitazine
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
Æä´ÏµåÁ¤10mg
G01000341
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Methylphenidate HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
Æä´ÏµåÁ¤5mg
G01000331
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Methylphenidate HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | ±Þ¿©
ȯÀγª·Ï¼ÕÁÖ2mg
A09702061
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Naloxone HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
ȯÀγª·Ï¼ÕÁÖ
A09701551
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Naloxone HCl
±¸ºÐ/º¸Çè±Þ¿©: Àü¹®ÀǾàǰ | »èÁ¦
¾Æ³«½ºÁ¤
A09701961
ÆÇ¸Å»ç: ȯÀÎÁ¦¾à
¼ººÐ/ÇÔ·®: Naproxen sodium
±¸ºÐ/º¸Çè±Þ¿©: ÀϹÝÀǾàǰ | ±Þ¿©
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
fantasy
ȯ»ó
phantasm
ȯ»ó
reverie
ȯ»ó
reverie
ȯ»ó;¸ù»ó;¸Á»ó;ȯ»ó°î
fantast
ȯ»ó°¡;¸ù»ó°¡
fantasist
ȯ»ó°î(ȯ»óÀû ÀÛǰ)À» ¾²´Â ÀÛ°î°¡(ÀÛ°¡);¸ù»ó°¡
fantasia
ȯ»ó°î;È¥¼º°î
loop line
ȯ»ó¼±
illusionsm
ȯ»ó¼³,¹Ì¸Á¼³(½ÇÀç ¼¼°è´Â ÇϳªÀÇ È¯¿µÀ̶ó°í ÇÏ´Â);ȯ°¢¹ý Ì´
visioned
ȯ»ó¿¡ ³ªÅ¸³;ȯ¿µ¿¡ ÀÇÇÑ;»ó»ó·Â(ÅëÂû·Â)ÀÌ Ç³ºÎÇÑ
visional
ȯ»óÀ¸·Î º»;Çã±úºñ(°îµÎ)ÀÇ;ȯ¿µÀÇ;ȯ¿µÀûÀÎ;¸ù»óÀûÀÎ;°¡°øÀÇ
annuloid
ȯ»óÀÇ
LinuX
ȯ»óÀÇ 32ºñÆ® ¿î¿µÃ¼Á¦;¾²¸é ¾µ¼ö·Ï ±× ÆÄ¿ö¿¡ ºüÁ®µé°ÍÀÌ´Ù. ´À²¸º¸¶ó ¸®´ª½ºÀÇ ÆÄ¿ö~
magic realism
ȯ»óÀû »ç½ÇÁÖÀÇ
fantasticate
ȯ»óÀûÀ¸·Î ÇÏ´Ù
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
stonehenge
ȯ¿¼®ÁÖ
subpena
¼ÒȯÀå
subpoena
¼ÒȯÇÏ´Ù
swap
±³È¯ÇÏ´Ù
trance
¸ùȯÀǰæÁö,ȲȦ,³ÌÀ»ÀÒ°í,½Ç½Å,ÀλçºÒ¼º,È¥¼ö»óÅÂ,½Ç½ÅÇÏ´Ù
transpose
¼·Î ¹Ù²ã³õ´Ù; ÀüȯÇÏ´Ù
transposition
Àüȯ
turn in
Á¦ÃâÇÏ´Ù; Á¢´Ù; ¹ÝȯÇÏ´Ù
ventilate
ȯ±â¸¦ ÇÏ´Ù
ventilation
ȯ±â
ventilator
ȯ±âÀåÄ¡
visionary
ȯ¿µÀÇ; °¡°øÀûÀÎ
welcome
ȯ¿µ¹Þ´Â
Aegisthus
¾ÆÀ̱⽺Ʈ½º(AgamemnonÀÇ ¾Æ³»¸¦ À¯È¤Çϰí,±ÍȯÇÑ ±×¸¦ »ìÇØ,³ªÁß¿¡ ±×ÀÇ ¾Æµé Orestes¿¡°Ô »ìÇØµÊ)
Annelida
ȯÇü µ¿¹°¹®
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
ÀÌÀü
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
ÀÌÀü
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
7
¿µ¹®
ÇѱÛ
¼³¸í
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
7
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½